Scorpius (SCPX) 10-Q2018 Q1 Quarterly report

Filed: 15 May 18, 7:31am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: agonist, analyzing, aswe, attempt, began, beneficial, biopharmaceutical, booster, capable, certificate, Codification, Companywill, compliance, compliant, confer, Conference, constituting, Continental, conventional, conversion, convertible, Delaware, demonstrated, description, deter, director, discourage, discouraging, duration, education, exact, extended, federal, fill, forthcoming, framework, frustrate, gain, government, guard, HCW, hostile, HS, Immunological, immunologically, incentive, inclusion, inclusive, IND, Innate, interdependent, interpretive, intradermal, ITT, Keystone, lab, liquid, liquidity, listing, LLC, lower, lowered, maturing, maturity, monotherapy, national, noncommercial, notice, notified, open, ourImPACT®and, overallotment, ownership, par, peripheral, poorly, population, predefined, prescribed, presentedinterim, prohibit, proportionately, protocol, provisional, PTX, ratio, readout, realized, reassessthe, reconciliation, recurrence, redeemed, regained, registered, remeasurement, removal, remove, request, requested, restated, retain, Riley, scan, segment, shock, shorter, showed, slightly, speculative, split, stockholder, subgroup, suspended, Symposia, takeover, TCAP, tender, TheImPACT, Trademark, tranche, transition, Trust, underwent, unlock, upcoming, uponImPACT, Wainwright

Removed: advantage, arise, arm, Australian, back, bank, biologic, cease, classification, conducting, consultant, consulting, cover, cytotoxic, decision, developed, devoting, directly, discrete, doubt, engineered, exhibited, expensed, GITR, headcount, hold, improve, incorporate, indemnification, independent, integral, investigator, kill, lieu, limiting, loan, longer, maker, mount, negotiated, occur, partnering, potent, preliminary, primary, proliferation, pursue, receivable, recently, reclassed, reduction, reimbursement, repaid, role, Rule, secondary, secreted, site, stimulator, suggest, synergistic, termination, tocomplete, tolerability, tomeet, travel, Unallocated, vector, vested, warranted, withholding

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SCPX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Heat Biologics, Inc. (the “Registrant”) hereby certifies, to such officer’s knowledge, that:


	(1)	the accompanying Quarterly Report on Form 10-Q of the Registrant for the quarter ended March 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and


	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.


Date: May 15, 2018

	By:	/s/ Jeffrey Wolf
		Name: Jeffrey Wolf
		Title: Chief Executive Officer
		(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.